Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines

摘要: While the importance of immunological adjuvants for optimal induction antibody and T-cell responses against tumor antigens is clear, relevant potency different not clear. We have screened 19 with KLH conjugate vaccines containing two human cancer (MUC1 peptide GD3 ganglioside) in mouse. ELISA assays IgM IgG as well proliferation cytokine release (IFN-gamma IL-4) were performed. Six stood out being especially effective antibodies both MUC1 GD3: QS-21, TiterMax, MoGM-CSF, MPL/DETOX CpG ODN. Of these MoGM-CSF uniformly at inducing potent IFN-gamma IL-4 while TiterMax ODN generated but less or release. Overall, our previous experience, QS-21 was most adjuvant. There no clear evidence immunity either any adjuvants. a strong correlation between induced strength KLH. This suggests that primary role context may be higher levels KLH, which then leads to conjugated antigens.